Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 56, Issue -, Pages 269-276Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2018.01.042
Keywords
IL-2; Effector T cells; Regulatory T cells; Autoimmune diseases
Categories
Funding
- National Natural Science Foundation of China [81273308]
- China State Key Research [2016YFA0501404]
Ask authors/readers for more resources
Although Interleukin-2 (IL-2) was identified almost 40 years ago, only recently low dosage IL-2 therapy is proved to be an effective approach to treat autoimmune diseases. The underlining mechanism is that IL-2 can fine-tune subsets of CD4(+) T cells by promoting the development and maintenance of regulatory T cells (Treg) at low dosage (ld) and enhance the functions of effector T cells (Teff) at high-dosage (hd). Since the successful clinical trials of IL-2 to treat patients with autoimmune diseases and inflammatory conditions, including Systemic lupus erythematosus (SLE) and Type 1 Diabetes (T1D), Id IL-2 therapy is a promising strategy to treat autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available